Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ovid · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ovid Therapeutics Inc. (OVID) measures how much investors pay for each dollar of the company's trailing earnings. OVID's current PE ratio of N/A is calculated by dividing its stock price of $2.36 by its TTM earnings per share of -$0.33.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ovid Therapeutics Inc.You OVID | $311M | N/A | — | -$0.33 |
 Clene Inc. CLNN | $55M | N/A | — | -$2.65 |
 Connect Biopharma Holdings Limited CNTB | $139M | N/A | — | -$1.00 |
 Context Therapeutics Inc. CNTX | $157M | N/A | — | -$0.38 |
 InflaRx N.V. IFRX | $124M | N/A | — | -$0.68 |
 ImageneBio Inc IMA | $64M | N/A | — | -$9.31 |
 Kalaris Therapeutics Inc KLRS | $78M | N/A | — | -$2.85 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.24 | — | |
2024-12-31 FY2024 | — | $-0.37 | — | |
2023-12-31 FY2023 | — | $-0.74 | — | |
2022-12-31 FY2022 | — | $-0.77 | — | |
2021-12-31 FY2021 | 1.76x | $1.82 | — | |
2020-12-31 FY2020 | — | $-1.39 | — | |
2019-12-31 FY2019 | — | $-1.54 | — | |
2018-12-31 FY2018 | — | $-2.11 | — | |
2017-12-31 FY2017 | — | $-3.35 | — | |
2016-12-31 FY2016 | — | $-1.14 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ovid Therapeutics Inc. (OVID) measures how much investors pay for each dollar of the company's trailing earnings. OVID's current PE ratio of N/A is calculated by dividing its stock price of $2.36 by its TTM earnings per share of -$0.33.
Frequently asked questions
OVID pe ratio · 6 questionsOVID's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.36 and TTM EPS of -$0.33. Data sourced from Financial Modeling Prep via OVID's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ovid Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09